Given the criteria above and the fact that YY1 could target TLR7 and TLR9 signaling, type I and II interferon production/pathways, reported as effective for virus clearance during infection, if activated, establishes YY1 as the best TF with the best potential as a drug target for BCoV therapy. Here, TF is linked to infection.